Mobile

Safety and efficacy of secukinumab compared to placebo and abatacept in patients with active rheumatoid arthritis who did not respond to anti-TNFα agents Sledování bezpečnosti a účinnosti secuki...

Update Il y a 4 ans
Reference: EUCTR2011-000102-21

Safety and efficacy of secukinumab compared to placebo and abatacept in patients with active rheumatoid arthritis who did not respond to anti-TNFα agents Sledování bezpečnosti a účinnosti secukinumabu v porovnání s placebem a abataceptem u pacientů s aktivní revmatoidní artritidou a nedostatečnou odpovědí na léčbu anti-TNFα

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Demonstrate the efficacy of secukinumab (75 or 150 mg) versus placebo (measured with ACR 20) after 24 weeks of treatment

Inclusion criteria

  • Rheumatoid Arthritis,Revmatoidní artritida

Links